InvestorsHub Logo
Followers 75
Posts 3034
Boards Moderated 0
Alias Born 06/01/2012

Re: John_Langston post# 180642

Monday, 01/25/2016 11:34:30 PM

Monday, January 25, 2016 11:34:30 PM

Post# of 403671
There has been much information post here since the run to .97, so that statement is truly misinformation.
FACT:
Elite has completed every trial the FDA has requested.
FACT:
Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study For Abuse-Deterrent Opioid ELI-200
Meets Primary and Secondary Endpoints
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain.
The pivotal trial met its primary endpoint (p = 0.001), demonstrating statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Secondary endpoint results were consistent with primary findings and included safety measures. There were no serious adverse events or deaths related to ELI-200 reported during the conduct of the trial.
FACT:
The highly touted sub-penny AQUM does not exist anymore.
FACT:
Elite has risen from the lows of .06 to the present day price of .36 since Nasrat Hakim became CEO.

anything posted by me is just my opinion and not meant to be considered advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News